<DOC>
	<DOCNO>NCT02120417</DOCNO>
	<brief_summary>This randomize , double-blind , placebo control clinical trial compare overall survival woman advance metastatic HER2-negative breast cancer receive treatment capecitabine combination ruxolitinib versus receive treatment capecitabine alone .</brief_summary>
	<brief_title>A Study Ruxolitinib Combination With Capecitabine Subjects With Advanced Metastatic HER2-negative Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Histologically cytologically confirm HER2negative adenocarcinoma breast Locally advance ( Stage 3B ) metastatic ( Stage 4 ) disease Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Received 2 prior chemotherapy regimen ( include neoadjuvant/adjuvant therapy ) advance metastatic disease Subjects hormonereceptor positive tumor must fail available appropriate line hormonal therapy ≥ 2 week elapse completion previous treatment regimen must recover new stable baseline relate toxicity Radiographically measurable evaluable disease An mGPS 1 2 define : Criteria : 1. mGPS 1 : CRP &gt; 10 mg/L albumin ≥ 35 g/L 2. mGPS 2 : CRP &gt; 10 mg/L albumin &lt; 35 g/L Received prior treatment capecitabine metastatic disease Received 2 prior chemotherapy regimen advance metastatic disease ( include neoadjuvant/adjuvant therapy ) Unknown hormonereceptor status Ongoing radiation therapy , radiation therapy administer within 2 week enrollment Inadequate renal , hepatic bone marrow function</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Breast Cancer</keyword>
</DOC>